Jeena Sikho Lifecare Limited has announced a series of significant developments, including receiving regulatory approvals for its Employee Stock Option Scheme and key leadership changes, positioning the company for strategic growth in the healthcare sector.

Stock Exchange Approvals for ESOP Scheme

The company has received crucial in-principle approvals from both major stock exchanges for its Employee Stock Option Scheme 2025. The approvals cover the listing of up to 2,50,000 equity shares of ₹2.00 each under the scheme.

These approvals represent a significant milestone following the Board's initial approval of the ESOP scheme on August 27, 2025. The scheme aims to benefit eligible employees and directors across the company and its group entities.

Leadership Appointments and Changes

The company appointed Sahil Jain as its new Chief Operating Officer, effective August 27, 2025. Jain brings over eight years of experience within the organization, having previously led key departments including IT, Marketing, Call Center Operations, and Administration. His background includes valuable experience at global technology firms IBM and HCL Australia.

In a significant board restructuring, Shreya Grover has been redesignated from Non-Executive Director to Whole-Time Director for a five-year term. Grover, daughter of Managing Director Manish Grover and associated with the company since June 2021, will focus on guiding growth strategies, including Ayurveda hospital expansion and OTC Ayurveda product launches.

Corporate Governance and Financial Decisions

The Board made several other strategic decisions during its August meeting:

These developments indicate the company's commitment to strengthening its operational framework while rewarding stakeholders through dividend distributions and employee participation schemes.

Strategic Positioning

The combination of regulatory approvals for the ESOP scheme, strategic leadership appointments, and governance enhancements suggests Jeena Sikho Lifecare is positioning itself for expansion in the Ayurveda and wellness sector. The company's focus on employee retention through stock options and operational efficiency through experienced leadership appointments demonstrates a comprehensive approach to sustainable growth.

Jeena Sikho Lifecare Limited , a prominent player in the alternative healthcare sector, has reported robust financial results for the second quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Financial Performance

The company's revenue from operations reached Rs. 190.00 crores in Q2FY26, marking a substantial 66% year-on-year growth from Rs. 114.00 crores in Q2FY25. This performance was complemented by a 9% quarter-over-quarter increase from Rs. 174.00 crores in Q1FY26.

Jeena Sikho's profitability saw a remarkable improvement, with profit after tax (PAT) surging 121% year-on-year to Rs. 59.00 crores. The company also reported a 15% quarter-over-quarter increase in PAT.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 129% year-on-year to Rs. 92.00 crores, maintaining a strong EBITDA margin of 48%.

Operational Highlights

The healthcare provider has expanded its bed capacity, adding 582 beds to reach a total of 2,802 beds. The company reported a 57% occupancy rate across its network of 58 hospitals and 59 clinics.

Jeena Sikho's geographical footprint now spans 23 states and over 100 cities, indicating a wide-reaching presence in the Indian healthcare market.

Strategic Partnerships and Expansion

Jeena Sikho announced a strategic partnership with Chandan Diagnostic. This collaboration provides the company access to 40 lakh privilege cardholders and facilitates the establishment of diagnostic centers across their network.

The partnership aims to enhance patient services by offering free basic blood tests, including ESR, uric acid, CBC, lipid profile, LFT, RFT, and thyroid profile.

Product Development and Technology Integration

The company plans to launch 10 new over-the-counter (OTC) products by the end of the year, expanding its product portfolio. Additionally, Jeena Sikho has partnered with Salesforce to improve data management and customer engagement, indicating a focus on technological integration to enhance operational efficiency.

Management Commentary

Manish Grover, Managing Director of Jeena Sikho Lifecare Limited, commented on the results: "Our continuous hard work and effort has given a great result. We have observed good revenue growth in our product and services segment. This expansional growth shows that we are strongly motivated towards spreading quality alternate health care services to a lot of people."

Grover also highlighted the company's focus on increasing bed occupancy and expanding service footprint, stating, "We are seeing tremendous growth in both our product and services verticals. And it is proof that we are continuously increasing the free cash generation revenue generation."

Future Outlook

While specific guidance for the full fiscal year was not provided, management indicated ongoing efforts to maintain operational efficiency while pursuing expansion. The company's focus on increasing bed occupancy, launching new products, and strategic partnerships suggests a continued growth trajectory in the alternative healthcare sector.

Jeena Sikho Lifecare's strong Q2 FY26 performance underscores its growing presence in the alternative healthcare market, with significant improvements in revenue, profitability, and operational scale.